After T-DXd: Target, Payload, or Something Else?

Why It Matters

Pinpointing the resistance mechanism enables clinicians to select the most effective subsequent therapy, directly influencing outcomes for HER2‑positive cancer patients.

Key Takeaways

• Payload loss and target loss both drive T‑DXd resistance
• Patient-specific mechanisms dictate next therapeutic choice
• Options include new HER2 ADCs, alternative payloads, combos
• Biomarker testing can identify resistance pathway
• Non‑HER2 strategies may be required for some patients

Pulse Analysis

Trastuzumab deruxtecan has reshaped the treatment landscape for HER2‑positive malignancies, delivering impressive response rates by coupling a HER2‑targeting antibody with a potent topoisomerase I inhibitor. Yet, as its use expands, clinicians are confronting a growing subset of patients whose tumors no longer respond. Two primary hypotheses dominate the conversation: the cytotoxic payload may become ineffective due to drug‑efflux mechanisms or DNA repair up‑regulation, and the tumor may down‑regulate HER2 or alter its internalization pathways, effectively evading the ADC’s delivery system. Both scenarios have been documented in early‑phase resistance studies, underscoring the need for nuanced diagnostics.

The practical implication is that a single biomarker cannot capture the complexity of T‑DXd failure. Comprehensive profiling—combining HER2 expression assays, circulating tumor DNA analysis for payload‑related resistance genes, and functional imaging of antibody uptake—can reveal whether a patient’s disease is payload‑driven or target‑driven. Such granularity informs the next line of therapy: patients with intact HER2 but resistant payload may benefit from a next‑generation ADC employing a different warhead, while those with HER2 loss might be steered toward non‑ADC options, such as kinase inhibitors or immunotherapy combinations. Early clinical trials are already testing these stratified approaches, highlighting the shift toward precision oncology.

Looking ahead, the field is exploring hybrid strategies that pair T‑DXd with agents that restore HER2 expression or inhibit efflux pumps, aiming to overcome both resistance axes simultaneously. Parallel development of novel ADC platforms—featuring cleavable linkers, alternative cytotoxins, and bispecific targeting—offers a pipeline of options for patients who have exhausted standard HER2‑directed therapies. Ultimately, integrating molecular diagnostics with adaptive treatment algorithms will be critical to maintaining the therapeutic momentum initiated by T‑DXd and ensuring durable benefits across diverse patient populations.